(Q33382803)

English

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

object named as

Jean-Yves Blay

0 references

Simone Mathoulin-Pélissier

12

object named as

Simone Mathoulin-Pelissier

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frederic Rolland

9

object named as

Frédéric Rolland

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

object named as

Nicolas Penel

2

0 references

Jacques-Olivier Bay

11

object named as

Jacques Olivier Bay

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

object named as

Antoine Thyss

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jérôme Fayette

1

object named as

Jérôme Fayette

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Chevreau

3

object named as

Christine Chevreau

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jean-Michel Coindre

13

object named as

Jean Michel Coindre

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Didier Cupissol

5

object named as

Didier Cupissol

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cécile Guillemet

7

object named as

Cécile Guillemet

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Maria Rios

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pierre Fargeot

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Binh Bui-Nguyen

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

16 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

482-489

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interim analyses in randomized clinical trials: ramifications and guidelines for practitioners.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soft-tissue sarcomas in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose response evaluation of adriamycin in human neoplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Soft tissue sarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence

1 reference

https://pubmed.ncbi.nlm.nih.gov/19148579

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-008-9217-1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33382803&oldid=2195306562"